Ewing Sarcoma - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 138 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ewing Sarcoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ewing Sarcoma - Pipeline Review, H1 2015', provides an overview of the Ewing Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ewing Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ewing Sarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Ewing Sarcoma - Overview 9
Pipeline Products for Ewing Sarcoma - Comparative Analysis 10
Ewing Sarcoma - Therapeutics under Development by Companies 11
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 13
Ewing Sarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Ewing Sarcoma - Products under Development by Companies 16
Ewing Sarcoma - Products under Investigation by Universities/Institutes 17
Ewing Sarcoma - Companies Involved in Therapeutics Development 18
3B Pharmaceuticals GmbH 18
Amgen Inc. 19
Cebiotex, S.L. 20
EntreChem, S.L. 21
Exelixis, Inc. 22
Gradalis Inc. 23
Kolltan Pharmaceuticals, Inc. 24
Merck & Co., Inc. 25
Merrimack Pharmaceuticals, Inc. 26
Novartis AG 27
Oncomatrix, S.L. 28
Recombio S.L 29
Shionogi & Co., Ltd. 30
Sigma-Tau S.p.A. 31
Tesaro, Inc. 32
Ewing Sarcoma - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
3BP-227 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
cabozantinib s-malate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
cancer vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CEB-01 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
celyvir - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
dactinomycin next generation - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
EC-8042 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
EC-8105 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ganitumab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
irinotecan sucrosofate liposomal - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KIT-SG3227 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibody Conjugated for Ewing Sarcoma - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MTX2-NIG - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
niraparib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pazopanib hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pembrolizumab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
racotumomab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
S-588410 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SP-2509 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SST-0001 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Ewing Sarcoma - Recent Pipeline Updates 92
Ewing Sarcoma - Dormant Projects 132
Ewing Sarcoma - Discontinued Products 133
Ewing Sarcoma - Product Development Milestones 134
Featured News & Press Releases 134
Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma 134
Nov 26, 2012: Possible New Treatment for a Childhood Cancer 134
Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 135
Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma 135
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

List of Tables

Number of Products under Development for Ewing Sarcoma, H1 2015 9
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Ewing Sarcoma - Pipeline by 3B Pharmaceuticals GmbH, H1 2015 18
Ewing Sarcoma - Pipeline by Amgen Inc., H1 2015 19
Ewing Sarcoma - Pipeline by Cebiotex, S.L., H1 2015 20
Ewing Sarcoma - Pipeline by EntreChem, S.L., H1 2015 21
Ewing Sarcoma - Pipeline by Exelixis, Inc., H1 2015 22
Ewing Sarcoma - Pipeline by Gradalis Inc., H1 2015 23
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015 24
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H1 2015 25
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 26
Ewing Sarcoma - Pipeline by Novartis AG, H1 2015 27
Ewing Sarcoma - Pipeline by Oncomatrix, S.L., H1 2015 28
Ewing Sarcoma - Pipeline by Recombio S.L, H1 2015 29
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2015 30
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2015 31
Ewing Sarcoma - Pipeline by Tesaro, Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 35
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H1 2015 92
Ewing Sarcoma - Dormant Projects, H1 2015 132
Ewing Sarcoma - Discontinued Products, H1 2015 133